TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›EHC
EHC logo

EHC

Encompass Health Corp

Next earnings Aug 3, 2026 (after close) · consensus $1.49 EPS, $1.59B rev

Last earnings -2.5% on 2026-04-30

Buy
$106.46
▲ +5.51%
$106.46▼ -12.30%
over 1Y
L $93.65H $126.70
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.5%
1W+6.8%
1M+4.8%
3M+9.3%
YTD+0.3%
1Y-12.3%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
B
Valuation
Undervalued
Filings
Flagged
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 17 analysts
Strong Buy

Largest US inpatient-rehab operator compounding revenue ~10%/yr with 23% ROE at a reasonable 17.7x P/E — demographic tailwind, buy.

Revenue (FY2025) $5.94B · FY2025

The read

Quality fundamentals and an attractive price line up (~98% below fair value) — the rarer case where both the business and the entry look good.

Encompass Health is the nation's largest owner-operator of inpatient rehabilitation hospitals (173 facilities across 39 states and Puerto Rico as of year-end 2025), and the financials show a steadily compounding, high-return business. Revenue grew 10.5% to $5.94B in FY2025, the fifth straight year of double-digit-ish gains (from $4.01B in FY2021), while net income rose 24.2% to $566M and diluted EPS climbed to $5.54. Net margin of 9.5%, return on equity of 23.2%, and $1.18B of operating cash flow point to durable, profitable growth driven by both volume and pricing per management's 2025 overview.

The balance sheet has materially strengthened: stockholders' equity rose 18.0% to $2.44B, retained earnings jumped 61.8% to $1.29B, and liabilities/equity sits at a manageable 1.56x. Management is returning capital while still investing heavily for growth — $158M of buybacks and $71.1M of dividends in FY2025, alongside $736M of capex funding a robust de novo pipeline (multiple new 40-60 bed hospitals opened in 2025 and a long list of 2026-2027 openings disclosed in the MD&A). Cash on hand is thin at $72.2M, but the strong operating cash generation comfortably funds this expansion.

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:44 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Is EHC a buy? The one-page verdict, explained →

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$4.01B$4.35B$4.80B$5.37B$5.94B
Gross profit—————
Operating income$560M$540M———
Net income$412M$271M$352M$456M$566M
Diluted EPS$4.11$2.70$3.47$4.46$5.54
Net margin10.3%6.2%7.3%8.5%9.5%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$11.7B
EV / EBITDA13.5
EV / Sales2.0
EV / FCF26.7
P / FCF24.0
PEG (trailing)0.79
Earnings yield5.4%
FCF yield4.2%

Quality & risk

ROIC (est.)11.7%
Free cash flow$439M
Total debt$1.22B
Net cash-$1.14B
Altman Z-Score3.02 safe
Piotroski F-Score8/8

Capital returns

Buyback yield1.5%
Dividend yield (est.)0.7%
Shareholder yield2.2%
Shares Δ YoY-1.3%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — agreement terminated (2026-03-10). Worth a closer look.
  1. 8-K Material agreement2026-06-01
  2. 8-K Material agreement2026-05-15
  3. 8-K Shareholder vote2026-05-11
  4. 10-Q Quarterly report2026-05-01
  5. 8-K Earnings results2026-04-30
  6. DEF 14A Proxy statement2026-04-07
  7. 8-K Agreement terminated2026-03-10
  8. 10-K Annual report2026-02-26
  9. 8-K/A Amended 8-K2026-02-20

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-05-292026-06-01open ↗4Period ending 2026-05-152026-05-18open ↗8-KPeriod ending 2026-05-142026-05-15open ↗144Filing2026-05-15open ↗4Period ending 2026-05-112026-05-12open ↗144Filing2026-05-11open ↗8-KPeriod ending 2026-05-072026-05-11open ↗4Period ending 2026-05-072026-05-11open ↗4Period ending 2026-05-072026-05-11open ↗4Period ending 2026-05-072026-05-11open ↗4Period ending 2026-05-072026-05-11open ↗4Period ending 2026-05-072026-05-11open ↗

Quality score

B
ValueGrowthProfitHealthMom.
ValueA-
GrowthB+
ProfitabilityB
Financial healthB
MomentumC-
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✓P/E below 25

Fair value est.

$210.43

Undervalued +98% vs price

cheapfair valueexpensive

Modified Graham: EPS $5.54 × (8.5 + 1.5 × 17.4% growth) × 1.10 quality = 38.0× multiple. An estimate, not a price target.

93.4752-week126.47
Revenue
$5.94B
+10.5% YoY
Net margin
9.5%
ROE
23.2%
P/E
19.2

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$5.94B+10.5%
Net income$566M+24.2%
Operating income$540M-3.6%
Diluted EPS$5.54+24.2%
Cash & equivalents$72.2M-15.5%
Total assets$7.09B+8.5%
Total liabilities$3.81B+3.5%
Stockholders' equity$2.44B+18.0%
Op.: 9.1%L/E: 1.56x

Frequently asked

Is Encompass Health Corp (EHC) a buy?
EHC currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Largest US inpatient-rehab operator compounding revenue ~10%/yr with 23% ROE at a reasonable 17.7x P/E — demographic tailwind, buy.
What is EHC's fair value?
A Modified-Graham model based on EHC's SEC fundamentals estimates a fair value of about $210.43. It is an estimate from reported earnings, not a price target.
Is EHC overvalued or undervalued?
Against a Modified-Graham fair-value estimate, EHC currently appears undervalued relative to its SEC-grounded earnings power.
What is Encompass Health Corp's quality score?
EHC scores 72.87703577085415/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000785161, latest 10-Q filed 2026-05-01) · EODHD · Proprietary analysis · as of 6/21/2026, 8:44:23 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 3 sales

2026-05-15
COLTHARP DOUGLAS E
EVP & Chief Financial Officer
Exercise27.7K @ $32.94$912K
2026-05-15
COLTHARP DOUGLAS E
EVP & Chief Financial Officer
Sell27.7K @ $106.83$2.96M
2026-05-15
COLTHARP DOUGLAS E
EVP & Chief Financial Officer
Sell1.00 @ $107.28$107.28
2026-05-11
Tuer Patrick William
EVP, Chief Operating Officer
Sell682.00 @ $104.56$71.3K
2026-05-07
O'Connor Kevin J.
Director
Award1.63K
2026-05-07
Christie Edward M III
Director
Award1.63K
2026-05-07
Reidy Christopher R
Director
Award1.63K
2026-05-07
Hayes Cain A
Director
Award1.63K
2026-05-07
CARMICHAEL GREG D
Director
Award1.63K
2026-05-07
Williams Terrance
Director
Award1.63K

Dividends

Quarterly
Yield (TTM)
0.7%
Annual / share
$0.76
Last ex-date
2026-07-01
Last amount
$0.19
ex 2026-07-01paid 2026-07-15$0.19
ex 2026-04-01paid 2026-04-15$0.19
ex 2026-01-02paid 2026-01-15$0.19
ex 2025-10-01paid 2025-10-15$0.19
ex 2025-07-01paid 2025-07-15$0.17
ex 2025-04-01paid 2025-04-15$0.17

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-04-30Beat +5.8% est▼ -2.54%8-K ↗
2026-02-05Beat +11.3% est▲ +4.08%8-K ↗
2025-10-29Beat +1.9% est▼ -0.51%8-K ↗
2025-08-04Beat +14.6% est▲ +0.89%8-K ↗
2025-04-24—▲ +0.69%8-K ↗
2025-02-06—▼ -3.52%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Congressional trades

all activity →

Disclosed under the STOCK Act

2025-11-21Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2020-10-07Susie LeeSell$1.00K–$15.0KPTR ↗
2020-06-15Susie LeeBuy$1.00K–$15.0KPTR ↗
2019-08-29Susie LeeSell$1.00K–$15.0KPTR ↗
2019-04-08Susie LeeBuy$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ ListBullish
finance.yahoo.com· 2026-07-02
William Blair updates conviction list: Oracle in, Meta out and moreBullish
seekingalpha.com· 2026-07-01
Can Encompass Health's Expansion Strategy Drive Its Next Growth Phase?Bullish
finance.yahoo.com· 2026-06-29
How HCA Stock's Quiet Compounding Changes The Growth StoryBullish
finance.yahoo.com· 2026-06-24
AI may help hospitals more than insurers, UBS saysBullish
seekingalpha.com· 2026-06-21
DaVita Expands Specialized Care Beyond Acute Settings Through IKCBullish
finance.yahoo.com· 2026-06-17

Vs tracked universe

compare →

1194 tracked peers · median

TENK Score73 vs 67
Revenue growth10.5% vs 7.5%
Net margin9.5% vs 10.0%
Return on equity23.2% vs 12.0%
P/E19.2 vs 26.2

News sentiment

EODHD · 27d
Bullish
+0.09
vs typical · 40 articles
↓ cooling

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.